Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.06), $0.05 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $6.92 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.